PDCD1 and head and neck squamous cell carcinoma: Adjuvant PD-1 blockade immunotherapy in combination with salvage surgery is being evaluated in multiple clinical trials as a means of improving the overall survival of patients with recurrent or metastatic HNSCC [100,101].